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Introduction {#sec005}
============

Acute kidney injury (AKI) is a frequent complication in patients hospitalized in the intensive care unit (ICU) and is associated with high mortality.\[[@pone.0223493.ref001], [@pone.0223493.ref002]\] Real replacement therapy (RRT) is the cornerstone of the management of AKI, although it could also be associated with complications and adverse events.\[[@pone.0223493.ref003], [@pone.0223493.ref004]\] There is, however, an ongoing debate concerning when to initiate it. Earlier initiation of RRT may help with fluid and electrolyte balance, removal of uremic toxins, and in the prevention of complications (e.g., metabolic encephalopathy and gastric hemorrhage). However, early initiation of RRT may unnecessarily expose a subset of patients who spontaneously recover renal function to potential harm.\[[@pone.0223493.ref005]\]

Despite the physiologic rationale, randomized controlled trials (RCTs) examining the ideal time for initiation of renal replacement therapy for AKI remains controversial.\[[@pone.0223493.ref006]--[@pone.0223493.ref010]\] Recent meta-analyses\[[@pone.0223493.ref011]--[@pone.0223493.ref015]\] suggested that early initiation of RRT is not associated with lower mortality rates; however, those studies have been limited by inconsistency, imprecision, and the risk of publication bias. Since these reviews, several large RCTs \[[@pone.0223493.ref016], [@pone.0223493.ref017]\] on the topic have been published. Given the conflicting evidence of RCTs and the limitations of the previous meta-analyses, we conducted an updated systematic review and meta-analysis to investigate the effect on mortality of the timing of the initiation of RRT in patients with AKI.

Methods {#sec006}
=======

In this systematic review and meta-analysis, we followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for the development of protocols and reporting of the study. **\[[@pone.0223493.ref018]\]** PRISMA checklist is reported in [S2 File](#pone.0223493.s002){ref-type="supplementary-material"}. Our protocol was registered at the international prospective register of systematic reviews (PROSPERO), number CRD42018115030.

Information sources and search strategy {#sec007}
---------------------------------------

A medical librarian searched Medline, Embase, Cochrane Database of Systematic Reviews from inception to October 15, 2018. ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform were searched to identify ongoing trials. The reference lists of included studies were searched for additional studies. There were no restrictions on language. Details of the search strategy are presented in" material A in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}'".

Eligibility criteria {#sec008}
--------------------

Studies were considered eligible if they met the following PICOS(Patients, Intervention, Comparison Outcomes, and Study design) criteria: (1) population: critically ill patients with AKI; (2) intervention: earlier initiation of RRT; (3) comparison intervention: late initiation of RRT; (4) outcome: at least one outcome of interest had to be reported; (5) study design: RCT. The definitions of the timing of initiation of RRT were at the discretion of the trials' authors.

Outcomes {#sec009}
--------

The primary outcome was short-term mortality (within 31 days). The secondary outcomes were long-term mortality (60--180 days), ICU length of stay, hospital length of stay, renal replacement therapy dependence, renal function recover, adverse events (metabolic acidosis, hyperkalemia, bleeding event, infection, and hypotension).

Study selection {#sec010}
---------------

After removal of duplicates, the title and abstracts of studies were independently screened in duplicate by two researchers (LX and YZ). The full texts of the remaining results were independently assessed in duplicate by the two researchers (LX and YZ) for inclusion based on predetermined criteria. Discrepancies were resolved by consensus among the study team.

Data collection process {#sec011}
-----------------------

One research (LX) abstracted data into standardized collection forms and created tables for the evidence and outcomes. Another research (YZ) double checked the extracted data. Discrepancies were resolved by consensus among the study team. We contacted corresponding authors for unpublished information.

Quality assessment {#sec012}
------------------

Two researchers (LX and YZ) independently assessed the risk of bias using the Cochrane Collaboration risk of bias tool. They evaluated the following domains: sequence generation, allocation concealment, blinding of patients and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other bias. Each domain was classified as either low, unclear, or high risk of bias. Discrepancies were resolved by consensus among the study team.

The grading of recommendations assessment, development, and evaluation (GRADE) approach was used to rate the quality of evidence and generate absolute estimates of effect for the outcomes to rate the quality of evidence for each outcome as high, moderate, low, or very low.\[[@pone.0223493.ref019]\]

Data synthesis {#sec013}
--------------

Analyses were conducted using Review Manager version 5.3.3 (Cochrane Collaboration). Summary measures were pooled using random-effects models. For continuous outcomes, the mean difference (MD) with 95% CI was calculated. For dichotomous outcomes, we calculated the relative risk (RR) with 95% CI. Statistical significance testing was 2-sided and a P \< .05 was considered statistically significant. Heterogeneity was assessed by I^2^ tests, with substantial heterogeneity defined as I^2^ greater than 50%.\[[@pone.0223493.ref020]\] We planned to assess publication bias using funnel plot inspection, Egger's test, Begg's test, and Harbord'test when 10 or more trials were pooled.

We performed multiple sensitivity analyses to investigate potential sources of inconsistency, including removal of individual trials at each time, removal of trials conducted before 2005, removal of trials including fewer than 100 patients, and removal of with non-low risk of bias of each domain.

We conducted prespecified subgroup analyses based on ICU type (surgical or mixed ICU), sepsis (yes or mixed), and type of RRT (continuous renal replacement therapy \[CRRT\], IHD \[intermittent hemodialysis\], or mixed). We also conducted meta-regression of control groups mortality to explore the effects of potential sources of heterogeneity.

A trial sequential analysis (TSA) using TSA software (version 0.9.5.9) was conducted to explore the minimum information size for the primary outcome. An optimal information size set to a two-sided 5% risk of a type I error, 20% risk of a type II error (power of 80%), and relative risk reduction of 20%.

Results {#sec014}
=======

Study selection and study characteristics {#sec015}
-----------------------------------------

The PRISMA flow diagram of the meta-analysis is shown in [Fig 1](#pone.0223493.g001){ref-type="fig"}. A total of 5,168 records were retrieved with 11 trials, including a total of 2242 participants, included in the study. \[[@pone.0223493.ref006]--[@pone.0223493.ref010], [@pone.0223493.ref016], [@pone.0223493.ref017], [@pone.0223493.ref021]--[@pone.0223493.ref024]\]

![Study selection for inclusion in meta-analysis of the timing of initiation of renal replacement therapy.](pone.0223493.g001){#pone.0223493.g001}

[Table 1](#pone.0223493.t001){ref-type="table"} and "Table A-B in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}" summarize the characteristics of the included trials. Population sizes ranged from 28 to 619, and five trials included more than 200 patients. Follow-up varied between 14 and 180 days.

10.1371/journal.pone.0223493.t001

###### Characteristics of included studies.

![](pone.0223493.t001){#pone.0223493.t001g}

  Author       Year   Country       Population          Patients (No)   Mean Age (year)   Male (%)   Follow-up (days)
  ------------ ------ ------------- ------------------- --------------- ----------------- ---------- ------------------
  Bouman       2002   Netherlands   Surgery / medical   106             68                60         28
  Durmaz       2003   Turkey        Cardiac Surgery     44              56                79         30
  Sugahara     2004   Japan         Cardiac Surgery     28              65                64         14
  Payen        2009   France        Medical/ Surgery    76              58                71         28
  Jamale       2013   India         Medical             208             43                68         90
  Combes       2015   France        Cardiac Surgery     224             59                79         90
  Wald         2015   Canada        Medical/ Surgery    100             63                72         90
  Gaudry       2016   France        Medical/ Surgery    619             66                65         60
  Zarbock      2016   Germany       Surgery             231             67                63         90
  Barbar       2018   France.       Medical             477             69                61         180
  Lumlertgul   2018   Thailand      Medical             118             67                49         28

Risk of bias of included trials is shown in "Figure A-B in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}". The Cochrane Collaboration's tool indicated that all trials were adjudicated as high risk of bias because treating clinicians were not blinded to treatment allocation and outcome assessment. [Table 2](#pone.0223493.t002){ref-type="table"} summarizes the findings of all outcomes.

10.1371/journal.pone.0223493.t002

###### Summary of findings and strength of evidence in trials comparing early vs late initiation of RRT.

![](pone.0223493.t002){#pone.0223493.t002g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                No. of patients\   Relative effect\   I^2^   Absolute effect estimates\   Quality                     
                                         (Studies)          (95% CI)                  (per 1000)                                               
  -------------------------------------- ------------------ ------------------ ------ ---------------------------- --------- ----------------- ------------------------------------------------
  Mortality short term (≤31 days)        2207\              RR 0.99\           44%    392                          392       0 (−59 to 67)     High
                                         (11)               (0.84 to 1.17)                                                                     

  Mortality long term (60--180 days)     1662\              **RR 0.98**\       42%    497                          487       −10 (−75 to 65)   High
                                         (5)                (0.85 to 1.13)                                                                     

  Length of stay in ICU                  1658\              MD 0.06\           0%     0.06 (-1.11 to 1.22)         High                        
                                         (6)                (-1.11 to 1.22)                                                                    

  Length of stay in hospital             1602\              MD -1.09\          25%    -1.09 (-3.53 to 1.36)        High                        
                                         (6)                (-3.53 to 1.36)                                                                    

  Renal function recovery                1579\              **RR 1.02**\       32%    549                          560       11(−16 to 38)     High
                                         (9)                (0.97 to 1.07)                                                                     

  Renal replacement therapy dependence   1036\              **RR 0.77**\       0%     71                           55        -16 (−36 to 15)   Moderate[^1^](#t002fn002){ref-type="table-fn"}
                                         (8)                (0.49 to 1.21)                                                                     

  Metabolic acidosis                     964\               **RR 0.65**\       10%    126                          82        -44 (−72 to -1)   Moderate[^1^](#t002fn002){ref-type="table-fn"}
                                         (4)                (0.43 to 0.99)                                                                     

  Hyperkalemia                           1583\              **RR 0.53**\       42%    63                           33        -30 (−47 to 6)    Moderate[^1^](#t002fn002){ref-type="table-fn"}
                                         (5)                (0.26 to 1.09)                                                                     

  Hypotension                            1020\              **RR 1.24**\       0%     275                          341       66 (22 to 118)    High
                                         (4)                (1.08 to 1.43)                                                                     

  Bleeding event                         1872\              **RR 0.95**\       10%    167                          159       -8 (40 to 33)     Moderate[^1^](#t002fn002){ref-type="table-fn"}
                                         (8)                (0.76 to 1.2)                                                                      

  Infection                              1877\              **RR 1.12**\       32%    152                          170       18 (−26 to 80)    Moderate[^1^](#t002fn002){ref-type="table-fn"}
                                         (8)                (0.83 to 1.53)                                                                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

^1^ imprecisions

Primary outcome {#sec016}
---------------

The associations between the timing of initiation of RRT and mortality are shown in [Fig 2](#pone.0223493.g002){ref-type="fig"}. There were 11 trials including a total of 2207 participants with data available regarding short-term (≤31 days) mortality. The pooled RR for short-term mortality for early versus late initiation of RRT was 0.99 (95% CI 0.84--1.17, p = 0.93, I^2^ = 44%). The TSA for the primary outcome showed a required information size was not met. All sensitivity analyses were consistent with the main analysis (Table C in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}).

![Association of early vs. delay of initiation of renal replacement therapy with short-term and long-term mortality.](pone.0223493.g002){#pone.0223493.g002}

Multiple subgroup analyses did not demonstrate any credible subgroup effect (p \> 0.05 for all outcomes, [Table 3](#pone.0223493.t003){ref-type="table"}). Meta-regression examining the effect of control group mortality on short-term mortality did not demonstrate the possible sources of heterogeneity. (P = 0.06, [Fig 3](#pone.0223493.g003){ref-type="fig"}).

![Meta-regression for short-term mortality outcome by control groups mortality (P = 0.06).](pone.0223493.g003){#pone.0223493.g003}

10.1371/journal.pone.0223493.t003

###### Subgroup analysis of the effect of early initiation of RRT on short-term mortality.

![](pone.0223493.t003){#pone.0223493.t003g}

  Subgroup title   No. of studies   No. of patients   Risk Ratio, 95%CI     P
  ---------------- ---------------- ----------------- --------------------- ------
  ICU type                                                                  
      Surgical     4                899               0.66 \[0.30, 1.48\]   0.29
      Mixed        11               1308              1.03 \[0.90, 1.17\]   
  Sepsis                                                                    
      Yes          2                564               1.10 \[0.91, 1.32\]   0.31
      Mixed        9                1643              0.94 \[0.75, 1.18\]   
  RRT type                                                                  
      IHD          5                1018              0.97 \[0.72, 1.31\]   0.91
      CRRT         2                252               0.62 \[0.06, 6.53\]   
      Mixed        4                937               1.00 \[0.86, 1.17\]   
  Overall          11               2207              0.99 \[0.84, 1.17\]   NA

CRRT, continuous renal replacement therapy; ICU, intensive care unit; IHD, intermittent hemodialysis; NA, not available

Funnel plot analysis suggested some asymmetry (Figure C in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}), and Egger test effects (p = 0.648), Begg's test (p = 0.100), and Harbord'test (p = 0.302), detected no significant publication bias.

Secondary outcomes {#sec017}
------------------

For long-term mortality, there were a total of 1622 participants from 1 trial\[[@pone.0223493.ref009]\] that reported mortality at 60 days, three trials\[[@pone.0223493.ref008], [@pone.0223493.ref010], [@pone.0223493.ref024]\] that reported mortality at 90 days, and one trial\[[@pone.0223493.ref016]\] that reported mortality at 180 days. The pooled RR for long-term mortality for early initiation of RRT compared to late initiation of RRT was 0.98 (95% CI 0.85--1.13, p = 0.76, I^2^ = 42%, [Fig 2](#pone.0223493.g002){ref-type="fig"}).

Pooled estimates suggest that different initiation of RRT result in similar ICU length of stay (MD 0.06 d, 95% CI -1.11 to 1.22, "Figure F in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}") and hospital length of stay (MD -1.09 d, 95% CI -3.53 to 1.36, "Figure F in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}"). There was no difference in the incidence of renal function recovery (RR 1.02, 95% CI 0.97--1.07, "Figure G in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}) and renal replacement therapy dependence (RR 0.77, 95% CI 0.49--1.21, "Figure H in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}) between early versus late of initiation of RRT.

Early initiation of RRT decreased the risk of metabolic acidosis (RR 0.65, 95% CI 0.43--0.99, p = 0.04, "Figure I in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}") but increased the risk of hypotension (RR 1.24, 95% CI 1.08--1.43, p = 0.003, "Figure J in [S1 File](#pone.0223493.s001){ref-type="supplementary-material"}").

Discussion {#sec018}
==========

In this meta-analysis of 11 RCT involving 2242 patients with AKI, we found that early initiation of RRT did not affect either short-term or long-term mortality. Subgroup analyses did not identify credible effect modification in ICU type (surgical or mixed ICU), sepsis (yes or mixed), and RRT type. The early strategy for the initiation of RRT was not associated with hospital length of stay, ICU length of stay, the recovery of renal function, and renal replacement therapy dependence. Furthermore, early initiation of RRT decreased the risk of metabolic acidosis but increased the risk of hypotension.

Principal findings and comparison with other studies {#sec019}
----------------------------------------------------

The most recent meta-analyses of RCTs have stated that early initiation of RRT is not associated with lower mortality rates. \[[@pone.0223493.ref011], [@pone.0223493.ref012], [@pone.0223493.ref014], [@pone.0223493.ref015], [@pone.0223493.ref025]\] It is consistent with our findings, but our study has narrower CIs and lower heterogeneity compared with the previous meta-analyses, which upgrades the quality of evidence from low to high. Furthermore, our study differs from previous studies in several ways. First, we separately reported mortality on the short-term and long-term basis. Second, this study included two recent trials\[[@pone.0223493.ref016], [@pone.0223493.ref017]\]. These data reinforced our findings, improved precision concerning the treatment effects of early initiation of RRT and decreased the heterogeneity of included trials. Third, we quantified two new findings, a reduced risk of metabolic acidosis and an increased risk of hypotension.

After this meta-analysis was submitted for initial review by PLOS ONE, Pasin et al. published an additional meta-analysis\[[@pone.0223493.ref026]\]. Their main conclusion was that early initiation of RRT in critically ill patients with AKI does not provide a clinically relevant advantage when compared with late initiation is like this study. However, this study found that early initiation of RRT decreased the risk of metabolic acidosis but increased the risk of hypotension. Moreover, the methodology of this study differs from that of Pasin et al.'s study. This study provided absolute as well as relative risks, explored the optimum sample size using TSA, and evaluated the quality of the evidence using GRADE approach.

Clinicians believe that earlier initiation of RRT confers a more prompt control of electrolyte and acid-base status, however, exposure to complications associated with RRT (eg, intradialytic hypotension, dysrhythmias, clearance of antibiotics) remains a concern.\[[@pone.0223493.ref005]\] This meta-analysis confirmed that metabolic acidosis is more frequent with late strategy whereas hemodynamic instability is more frequent with early strategy. We should weigh pros and cons more carefully to consider the clinical consequences of metabolic acidosis and hemodynamic instability. Though metabolic acidosis is more common than hypotension, hypotension has much more severe consequences than metabolic acidosis. Metabolic acidosis is very well tolerated and easy to correct with sodium bicarbonate administration\[[@pone.0223493.ref027]\], but hypotension is associated with increased mortality and a lower likelihood of renal recovery after AKI.\[[@pone.0223493.ref028]\]

Strengths and limitations {#sec020}
-------------------------

Methodological strengths of this study include a comprehensive search for evidence, rigorous assessment of the quality of evidence, specification of both relative and absolute effects, application of the TSA to explore the minimum information size and use of meta-regression to explore the effect.

Our study also has limitations. First, this study is limited by clinical heterogeneities among the included trials. Those variabilities included eligibility criteria, RRT modalities, ICU setting, length of follow-up, definition of AKI, and definition of "earlier" RRT. For example, inclusion criteria across trials is mostly based on functional changes in serum creatinine and/or urine output, whereas Zarbock et al.'s trial used neutrophil gelatinase--associated lipocalin. These heterogeneities may have influenced the effect of early initiation of RRT. Second, all trials have a high risk of bias because of unblinded design. Hhowever, it was difficult to perform a double-blind method study. Third, this study separately assessed both short-term (within 31 days), and long-term (60--90 days) mortality. However, the effect of early initiation of RRT on morality longer than 180 days was unclear, because no trial reported mortality longer than 180 days.

Applicability {#sec021}
-------------

Based on the findings of our study, high certainty evidence suggests no reduction in mortality with early initiation of RRT in AKI, which appear consistent across all studied subgroups. Thus, the adoption of early initiation of RRT in critically ill patients with AKI cannot be recommended for routine use unless further high quality and well-powered evidence shows the benefit of it. Additionally, an individual participant data meta-analysis would allow a more accurate assessment of the effect of earlier initiation of RRT on time-to-event and subgroup analysis.

Conclusions {#sec022}
-----------

High-quality evidence suggests that early versus later initiation of RRT in critically ill patients with AKI had no significant effect on mortality, although it reduces the risk of metabolic acidosis. Based on the limitations of this study (e.g., the heterogeneity of entry criteria), ongoing trials should clarify (1) the special population to target; (2) the optimal defemination of early versus later initiation of RRT; (3) the heterogeneity of RRT deliverables. Further large RCTs are required to confirm the result of this meta-analysis.
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AKI

:   Acute kidney injury

ICU

:   intensive care unit

RRT

:   renal replacement therapy

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-analyses

RCT

:   randomized controlled trial

PICOS

:   Patients, Intervention, Comparison Outcomes, and Study design

GRADE

:   the grading of recommendations assessment, development, and evaluation

RR

:   relative risk

TSA

:   trial sequential analysis
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